心血管

订阅

MedSci主页 / 所有栏目 / 心血管

两岸三地学者共同在《Nature》发文，称发现动脉粥样硬化形成新机制

2016-12-15 佚名 天津医科大学官网

动脉粥样硬化炎症YAP/TAZ
关注

近日，天津医科大学、香港中文大学生物医学学院和台湾细胞及系统医学研究所合作完成的一项研究发现一种名为YAP/TAZ的血管内皮细胞转录调控因子与动脉粥样硬化形成及血管炎症有密切关系。 这一结果发表在《Nature》上。血管内皮细胞是形成血管内壁表面的细胞层，而YAP/TAZ是这种细胞的转录调控因子，YAP/TAZ本身被视为“癌基因”，会促进癌症的发生及发展。而本研究发现，抑制YAP/TAZ活性还有助

近日，天津医科大学、香港中文大学生物医学学院和台湾细胞及系统医学研究所合作完成的一项研究发现一种名为YAP/TAZ的血管内皮细胞转录调控因子与动脉粥样硬化形成及血管炎症有密切关系。 这一结果发表在《Nature》上。

血管内皮细胞是形成血管内壁表面的细胞层，而YAP/TAZ是这种细胞的转录调控因子，YAP/TAZ本身被视为“癌基因”，会促进癌症的发生及发展。

而本研究发现，抑制YAP/TAZ活性还有助推迟动脉粥样硬化形成及抑制血管炎症。且YAP/TAZ的活性受不同血流动力模式所调控。

研究者指出，血液在血管内的流动方式分为层流和湍流。层流带来的血液与血管内壁摩擦力（又称“剪切应力”）会抑制YAP/TAZ的活性，进而减弱促使炎症发生的JNK信号传导和相关炎症基因的表达，减少单核细胞对内皮细胞的黏附。反之湍流则会增加YAP/TAZ的活性， 从而造成炎症的发生。

此项研究还发现几种现有的降血脂或抗动脉粥样硬化药物可抑制YAP/TAZ转录激活，以他汀类效果最为显著。


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881521, encodeId=944f1881521ee, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 03 00:55:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944426, encodeId=a9eb19444264f, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Feb 06 18:55:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174980, encodeId=7a3d1e49803b, content=感染、炎症、增生, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d2594380, createdName=longbo1206, createdTime=Wed Feb 08 16:47:06 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164231, encodeId=fac8164231f8, content=加强学术交流。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Dec 20 06:53:47 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163022, encodeId=5ae2163022fa, content=谢谢作者的分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJHmctib8wsjB1Y0etxU20nsCbR8rZ2fpibp2STmwH2YzicIsTe9oHRGB6XIMeBqNdIvxODicmzfeQibIw/132, createdBy=82211964557, createdName=清幽蓝燕yan, createdTime=Thu Dec 15 12:35:20 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163014, encodeId=11e516301405, content=关注，值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83821977043, createdName=我爱光明2009, createdTime=Thu Dec 15 11:49:41 CST 2016, time=2016-12-15, status=1, ipAttribution=)]
    2017-09-03 liye789132251

    #Nat#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1881521, encodeId=944f1881521ee, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 03 00:55:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944426, encodeId=a9eb19444264f, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Feb 06 18:55:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174980, encodeId=7a3d1e49803b, content=感染、炎症、增生, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d2594380, createdName=longbo1206, createdTime=Wed Feb 08 16:47:06 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164231, encodeId=fac8164231f8, content=加强学术交流。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Dec 20 06:53:47 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163022, encodeId=5ae2163022fa, content=谢谢作者的分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJHmctib8wsjB1Y0etxU20nsCbR8rZ2fpibp2STmwH2YzicIsTe9oHRGB6XIMeBqNdIvxODicmzfeQibIw/132, createdBy=82211964557, createdName=清幽蓝燕yan, createdTime=Thu Dec 15 12:35:20 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163014, encodeId=11e516301405, content=关注，值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83821977043, createdName=我爱光明2009, createdTime=Thu Dec 15 11:49:41 CST 2016, time=2016-12-15, status=1, ipAttribution=)]
    2017-02-06 huangshifeng

    #粥样硬化#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1881521, encodeId=944f1881521ee, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 03 00:55:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944426, encodeId=a9eb19444264f, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Feb 06 18:55:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174980, encodeId=7a3d1e49803b, content=感染、炎症、增生, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d2594380, createdName=longbo1206, createdTime=Wed Feb 08 16:47:06 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164231, encodeId=fac8164231f8, content=加强学术交流。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Dec 20 06:53:47 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163022, encodeId=5ae2163022fa, content=谢谢作者的分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJHmctib8wsjB1Y0etxU20nsCbR8rZ2fpibp2STmwH2YzicIsTe9oHRGB6XIMeBqNdIvxODicmzfeQibIw/132, createdBy=82211964557, createdName=清幽蓝燕yan, createdTime=Thu Dec 15 12:35:20 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163014, encodeId=11e516301405, content=关注，值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83821977043, createdName=我爱光明2009, createdTime=Thu Dec 15 11:49:41 CST 2016, time=2016-12-15, status=1, ipAttribution=)]
    2017-02-08 longbo1206

    感染、炎症、增生

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1881521, encodeId=944f1881521ee, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 03 00:55:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944426, encodeId=a9eb19444264f, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Feb 06 18:55:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174980, encodeId=7a3d1e49803b, content=感染、炎症、增生, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d2594380, createdName=longbo1206, createdTime=Wed Feb 08 16:47:06 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164231, encodeId=fac8164231f8, content=加强学术交流。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Dec 20 06:53:47 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163022, encodeId=5ae2163022fa, content=谢谢作者的分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJHmctib8wsjB1Y0etxU20nsCbR8rZ2fpibp2STmwH2YzicIsTe9oHRGB6XIMeBqNdIvxODicmzfeQibIw/132, createdBy=82211964557, createdName=清幽蓝燕yan, createdTime=Thu Dec 15 12:35:20 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163014, encodeId=11e516301405, content=关注，值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83821977043, createdName=我爱光明2009, createdTime=Thu Dec 15 11:49:41 CST 2016, time=2016-12-15, status=1, ipAttribution=)]
    2016-12-20 jyzxjiangqin

    加强学术交流。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1881521, encodeId=944f1881521ee, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 03 00:55:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944426, encodeId=a9eb19444264f, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Feb 06 18:55:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174980, encodeId=7a3d1e49803b, content=感染、炎症、增生, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d2594380, createdName=longbo1206, createdTime=Wed Feb 08 16:47:06 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164231, encodeId=fac8164231f8, content=加强学术交流。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Dec 20 06:53:47 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163022, encodeId=5ae2163022fa, content=谢谢作者的分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJHmctib8wsjB1Y0etxU20nsCbR8rZ2fpibp2STmwH2YzicIsTe9oHRGB6XIMeBqNdIvxODicmzfeQibIw/132, createdBy=82211964557, createdName=清幽蓝燕yan, createdTime=Thu Dec 15 12:35:20 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163014, encodeId=11e516301405, content=关注，值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83821977043, createdName=我爱光明2009, createdTime=Thu Dec 15 11:49:41 CST 2016, time=2016-12-15, status=1, ipAttribution=)]
    2016-12-15 清幽蓝燕yan

    谢谢作者的分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1881521, encodeId=944f1881521ee, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 03 00:55:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944426, encodeId=a9eb19444264f, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Feb 06 18:55:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174980, encodeId=7a3d1e49803b, content=感染、炎症、增生, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d2594380, createdName=longbo1206, createdTime=Wed Feb 08 16:47:06 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164231, encodeId=fac8164231f8, content=加强学术交流。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Dec 20 06:53:47 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163022, encodeId=5ae2163022fa, content=谢谢作者的分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJHmctib8wsjB1Y0etxU20nsCbR8rZ2fpibp2STmwH2YzicIsTe9oHRGB6XIMeBqNdIvxODicmzfeQibIw/132, createdBy=82211964557, createdName=清幽蓝燕yan, createdTime=Thu Dec 15 12:35:20 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163014, encodeId=11e516301405, content=关注，值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83821977043, createdName=我爱光明2009, createdTime=Thu Dec 15 11:49:41 CST 2016, time=2016-12-15, status=1, ipAttribution=)]
    2016-12-15 我爱光明2009

    关注，值得借鉴

    0

相关资讯

Nat Commun：双基因激活或和动脉粥样硬化发生直接相关

图片来源：www.sciencedaily.com 近日，来自布莱根妇女医院的研究人员通过研究发现了两个治疗动脉疾病（比如动脉粥样硬化）的潜在药物靶点，通过利用蛋白质组学对大量分子进行筛选，研究者鉴别出了两种PARP家族蛋白：PARP9和PARP14，这两种蛋白或许能够作为巨噬细胞激活的调节子，而巨噬细胞的激活同动脉疾病的发生直接相关，相关研究刊登于国际杂志Nature Communicat

Atherosclerosis：动脉粥样程度并不影响生物标志物与心血管疾病的相关性

背景：已经分别研究了心血管疾病（CVD）与生物标志物和动脉粥样硬化成像的相关性，但是动脉粥样硬化程度是否影响生物标志物与心血管疾病的相关性的研究较少。在这项研究中，研究者评估一级预防队列中，颈动脉内膜中层厚度（CIMT）评估的动脉粥样硬化是否影响与冠心病（CHD）和心血管疾病（CVD）相关的生物标志物的相关性。方法:在ARIC研究中根据动脉粥样硬化的程度（cIMT），将8127名（第四次访问，19

Circulation：中国-PAR计划——制定我国10年动脉粥样硬化心血管病的预测模型

背景：对个人风险的准确评估对指导和预防动脉粥样硬化性心血管疾病（ASCVD）是很有价值的。然而，常用的预测模型主要是在白人人群中制定的。这个项目的目的是开发和验证中国人群ASCVD的十年风险预测模型。方法: 21320中国受试者中，对两个前瞻性研究统一进行随访作为推导队列形成10年ASCVD风险预测模型。有123 14和838 70名受试者的两个独立的中国队列中进行外部验证。此外，与美国心脏病学会

葛均波 孔灵芝 陈韵岱 孟宪励——膳食胆固醇究竟要不要控制？

目前从学术界到广大民众普遍关心一个热点话题：膳食胆固醇的摄入究竟要不要进行限制？这个问题正如哈姆雷特的那句“To be or not to be, that is the question.”不同的对象、不同的环境、不同的程度，自然会带来不同的结局。因此从这个意义而言，邀请权威专家讨论正是为了明确其界限，让科学的认知引导广大民众，及时传递对胆固醇的正确认识。问：胆固醇是导致动脉粥样硬化性心脏病

JACC：Canakinumab对动脉粥样硬化患者的血管结构或功能无显著影响

有证据表明，白细胞介素（IL）-1β在动脉粥样硬化及其并发症发病机制中有重要的作用，抑制IL-1β对于血管疾病进展有利。来自英国的研究人员开展了一项研究，这项研究的目的是评估canakinumab vs 安慰剂抑制IL-1β与对动脉结构和功能的影响，由磁共振成像进行测定。患有动脉粥样硬化疾病和2型糖尿病或葡萄糖耐量降低的患者（n=189）随机接受安慰剂（n=94）或canakinumab每月150

盘点：近期动脉粥样硬化相关研究进展

动脉粥样硬化（atherosclerosis，AS）是冠心病、脑梗死、外周血管病的主要原因，是动脉壁上沉积一层包括胆固醇结晶在内的粥样物质，使动脉弹性降低、管腔变窄，常导致心肌梗塞、中风等致命疾病发生。胆固醇结晶会引发免疫反应，导致动脉壁出现可致命的炎症。关于近期动脉粥样硬化相关研究重大成果，小M与您分享。【1】SCI TRANSL MED：预防动脉粥样硬化的新方法——补充棕榈油酸虽然脂肪类食